Literature DB >> 4185247

C3 leukotactic factors produced by a tissue protease.

J H Hill, P A Ward.   

Abstract

When various rat tissues are incubated in homologous serum, a factor chemotactic in vitro for neutrophils is generated. The amount of chemotactic activity is a function of duration of incubation and the quantity of heart tissue or serum employed. Addition of trypsin inhibitor or antibody to the third component of complement (C3) precludes generation of chemotactic activity. In addition, antibody to C3 ablates chemotactic activity even after its formation. Purified human C3 (beta(1C)-globulin) effectively substitutes for serum in the generation of chemotactic activity by heart tissue. The active product, as determined by gel filtration or by ultracentrifugal analysis in a sucrose density gradient, appears to be a cleavage product of C3 with a molecular weight of approximately 14,000. In addition, a larger C3 fragmentation product varying in molecular weight, depending upon experimental conditions, is also found. The protease in rat heart tissue capable of cleaving C3 into chemotactic fragments is a serine esterase with trypsin-like properties and can be inhibited by organophophorous compounds or trypsin inhibitors. The use of amino acid esters in the manner of competitive substrate inhibition confirms the trypsin-like nature of the protease. The presence of a protease in heart, and presumably in other normal tissues, capable of fragmenting C3 into factors with chemotactic activities may explain the development of the acute inflammatory response when tissues are non-specifically injured. If true, this would reinforce the role of the complement system in the mediation of nonimmunologically induced inflammation.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4185247      PMCID: PMC2138703          DOI: 10.1084/jem.130.3.505

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Further studies on the chemotactic factor of complement and its formation in vivo.

Authors:  P A Ward; C G Cochrane; H J Muller-Eberhard
Journal:  Immunology       Date:  1966-08       Impact factor: 7.397

2.  Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement.

Authors:  H S Shin; R Snyderman; E Friedman; A Mellors; M M Mayer
Journal:  Science       Date:  1968-10-18       Impact factor: 47.728

3.  The gel-filtration behaviour of proteins related to their molecular weights over a wide range.

Authors:  P Andrews
Journal:  Biochem J       Date:  1965-09       Impact factor: 3.857

4.  Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement.

Authors:  A P Dalmasso; H J Müller-Eberhard
Journal:  J Immunol       Date:  1966-11       Impact factor: 5.422

5.  Anaphylatoxin in its relation to the complement system.

Authors:  J Jensen
Journal:  Science       Date:  1967-03-03       Impact factor: 47.728

6.  Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes.

Authors:  R Snyderman; H Gewurz; S E Mergenhagen
Journal:  J Exp Med       Date:  1968-08-01       Impact factor: 14.307

7.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

8.  Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes.

Authors:  E L Becker; P A Ward
Journal:  J Exp Med       Date:  1967-06-01       Impact factor: 14.307

9.  A plasmin-split fragment of C'3 as a new chemotactic factor.

Authors:  P A Ward
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  27 in total

1.  A unique complement derived chemotactic factor for tumor cells.

Authors:  A G Romualdez; P A Ward
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  Production of lymphokine-like factors (cytokines) by simian virus 40-infected and simian virus 40-transformed cells.

Authors:  P E Bigazzi; T Yoshida; P A Ward; S Cohen
Journal:  Am J Pathol       Date:  1975-07       Impact factor: 4.307

3.  Stimulating effect of neutral proteases on cells in vitro.

Authors:  T L Vischer; L Bertrand
Journal:  Agents Actions       Date:  1976-02

4.  Time course studies on the initiation of complement activation in acute myocardial infarction induced by coronary artery ligation in rats.

Authors:  Miriyala Sumitra; Panchatcharam Manikandan; Mohammed Nayeem; Bhakthavatsalam Murali Manohar; Beema Lokanadam; Subbiah Vairamuthu; Samu Subramaniam; Rengarajulu Puvanakrishnan
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 5.  Chemotaxis and its significance for leucocyte accumulation.

Authors:  H U Keller
Journal:  Agents Actions       Date:  1972-06

6.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

7.  Maturation of the human complement system. I. Onset time and sites of fetal C1q, C4, C3, and C5 synthesis.

Authors:  P F Kohler
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

8.  [Activation of complement--an exclusive domain of immune complexes?].

Authors:  D Bitter-Suermann
Journal:  Klin Wochenschr       Date:  1972-03-15

Review 9.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

10.  Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction.

Authors:  R N Pinckard; M S Olson; P C Giclas; R Terry; J T Boyer; R A O'Rourke
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.